Tara Lin

28PUBLICATIONS

140CO-AUTHORS

Medical molecular engineering of nucleic acids and proteinsData qualityGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Audiology

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (28)

Sort by Publication Date:

|Jul 03, 2026

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

|Jun 02, 2026

Near-Real-Time Clinical Trial Accrual Dashboard in a National Cancer Institute-Designated Cancer Center: Mixed Methods Implementation Study.

|Jun 02, 2026

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

|May 23, 2026

Correction: CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis.

|Mar 13, 2026

Does age matter? Optimizing AML treatment in older adults.

Catherine Lai, Tara L Lin

|Feb 24, 2026

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos

Pageof 5

Frequent Collaborators

Yazan F Madanat

Brian J Druker

Alice S Mims

Joshua Zeidner

Stephen A Strickland

Vu H Duong

Fieke W Hoff

Rina Li Welkie

Michael W Deininger

Ross L Levine

Frequent Collaborators

Yazan F Madanat

Brian J Druker

Alice S Mims

Joshua Zeidner